Identification of 'super-responders' to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry.
OBJECTIVE
Some patients show such an important clinical improvement and reverse remodelling after cardiac resynchronization therapy (CRT) that anatomy and function approach normal. These patients have been called 'super-responders'. The aim of our study was to identify predictors of becoming a super-responder after CRT.


RESULTS
Eighty-seven consecutive patients who underwent CRT were prospectively studied. Before CRT and 6 months after, clinical and echocardiographic evaluation was performed. Patients with a decrease in New York Heart Association functional class >or=1, a two-fold or more increase of left ventricular ejection fraction (LVEF) or a final LVEF >45%, and a decrease in LV end-systolic volume >15% were classified as super-responders. There were 12% super-responders. At baseline, there were no significant differences between super-responders and the other patients, except for the fact that super-responders had significantly smaller mitral regurgitation and LV end-diastolic diameter (LVEDD) and a shorter duration of heart failure symptoms. Mitral regurgitation jet area, LVEDD, and duration of heart failure symptoms were correlated with this super-response. Moreover, an evolution of symptoms for <12 months was an independent predictor of super-response to CRT.


CONCLUSIONS
Patients in earlier phases of the cardiomyopathy, with a less altered ventricular geometry, seem to have a greater probability of becoming super-responders.
António
Natália
N
Department of Cardiology, Coimbra University Hospital and Medical School, Avenida Bissaya Barreto, 3000-076 Coimbra, Portugal. natalia.antonio@gmail.com
Teixeira
Rogério
R
Coelho
Lourenço
L
Lourenço
Carolina
C
Monteiro
Pedro
P
Ventura
Miguel
M
Cristóvão
João
J
Elvas
Luís
L
Gonçalves
Lino
L
Providência
Luís A
LA
D002304:Cardiac Pacing, Artificial / Q000706:statistics & numerical data*; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control*; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011174:Portugal / Q000453:epidemiology; D011379:Prognosis; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control*